ABSTRACT It has been suggested that cytochrome P450 3A4 (CYP3A4) and MDR1 P-glycoprotein (Pgp) act synergistically to limit the bioavailability of orally administered agents. In order to determine the relative role of these proteins, it is essential to identify a selective inhibitor for either P-gp or CYP3A4. In the present investigation, comparative studies were performed to examine the effect of inhibitors on the function of these proteins. The IC 50 of P-gp function, determined by examining the inhibition of the transcellular transport of vinblastine across Caco-2 monolayers, was in the order PSC833 << ketoconazole, verapamil << N-(2(R)-hydroxy-1(S)-indanyl)-5-(2(S)-(1,1-dimethylethylaminocarbonyl)-4-(furo(2,3-b)pyridin-5-yl)methyl)piperazin-1-yl)-4(S)-hydroxy-2(R)-phenylmethylpentanamide (L-754,394). In contrast, the IC 50 of CYP3A4 function, determined by examining the inhibition of the metabolism of midazolam by intestinal and liver microsomes, was in the order L-754,384 < ketoconazole << PSC 833 and verapamil. The ratio of IC 50 for P-gp to that for CYP3A4 was more than 200 for L-754,394, 60 ~ 150 for ketoconazole, 1.5 for verapamil, and 0.05 for PSC 833. Collectively, it was demonstrated that PSC 833 and L-754,394 can be used as selective inhibitors of P-gp and CYP3A4, respectively.
INTRODUCTION
Based on the finding that intestinal epithelial cells contain significant amounts of metabolic enzymes (such as cytochrome P-450 3A4 (CYP3A4)), it has been suggested that the limited oral bioavailability of certain drugs can be ascribed to their first-pass elimination in the small intestine (1) . The results of subsequent pharmacokinetic analysis of the data obtained in human subjects who were given substrates (such as cyclosporin A) i.v. and p.o. are consistent with this hypothesis (2, 3, 4) . The direct demonstration of the validity of this hypothesis has been provided by examining the metabolic activity of midazolam, a CYP3A4 probe, during a survey of liver transplant recipients (5) . Under anhepatic conditions, the fraction of midazolam metabolized during transcellular transport across the intestinal epithelial cells after intraduodenal administration was found to be as high as 0.43 (5) .
In addition to CYP enzymes, MDR1 P-glycoprotein (P-gp), located on the brush border membrane of intestinal epithelium, may have a functional significance in limiting the oral bioavailability of its substrates (reviewed by Wacher et al. (6) ). This hypothesis was proved directly by studies in mdr1a/1b knockout mice, in which reduced small intestinal excretion and enhanced oral bioavailability have been reported (7, 8) . Focusing on the fact that the substrates of CYP3A4 and P-gp are mutually overlapping (1), Benet and his collaborators proposed that these proteins act synergistically to present a barrier to absorption from the small intestine (1, 6) . The results of a series of experiments in which the simultaneous administration of inhibitors of CYP3A4/P-gp increased the oral bioavailability of substrates are consistent with this hypothesis (9, 10, 6) . In addition, we have previously demonstrated the synergistic role of CYP3A4 and Pgp by simulation studies using a pharmacokinetic model in which the intracellular diffusion process has been considered (11).
Because, in general, inhibitors for CYP3A4 inhibit P-gp function (6), the relative role of CYP3A4 and P-gp in reducing the oral bioavailability still needs to be clarified. The purpose of the present study is to identify a selective inhibitor of either CYP3A4 or Pgp. Comparative studies were performed to examine the IC 50 of four kinds of CYP3A4/P-gp inhibitors on 2 these two proteins. P-gp and CYP3A4 activity was monitored by measuring the transcellular transport of vinblastine across Caco-2 monolayers, and the metabolic conversion of midazolam to -OH midazolam in human liver and small intestinal microsomes (12,13). 
MATERIALS AND METHODS

Materials
PSC 833, N-(2(R)-hydroxy-1(S)-indanyl)-5-(2(S)- (1,1-dimethylethyl-aminocarbonyl)-4-(furo(2,3- b)pyridin-5-yl)methyl)piperazin-1-yl)-4(S)-hydroxy- 2(R)-
Transcellular Transport Studies
Transcellular transport studies across the Caco-2 monolayer were performed according to the method described by Hunter et al. (14) . Caco-2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/l glucose, 5% fetal bovine serum (FBS), 0.1 mM non-essential amino acids, 4 mM L-glutamine and antibiotics/antifungal agents in an atmosphere of 95% O 2 -;5% CO 2 . Monolayers of Caco-2 cells, formed by incubating the confluent cells for an additional 20 days, were used for the transcellular transport studies. Each Caco-2 monolayer was washed twice with phosphate buffered saline (PBS) prior to the preincubation for 30 minutes in DMEM containing no FBS. Transcellular transport experiments were initiated by adding ( 3 H)vinblastine (100 nM) to the apical or basal side. At 1, 2, and 4 hours, aliquots of medium in the receiver side were removed to determine the radioactivity in a liquid scintillation counter (Model 2500TR, Packard, CA). Permeability of vinblastine across the monolayer (P app ) was calculated from the following equation:
where S, C 0 , and A represent the surface area of the Caco-2 monolayer, initial concentration of vinblastine in the donor side, and amount of vinblastine transferred to the receiver side, respectively.
Metabolic Studies
The metabolism of midazolam was examined according to the method described previously (12,13). 100 mM potassium phosphate buffer (pH 7.4) containing human microsomes (0.2 mg protein/ml), 9.63 mM glucose-6-phosphate, 0.356 mM NADP, 0.1 U/ml glucose-6-phosphate dehydrogenase and 0.25 mM EDTA, with or without inhibitors, were preincubated at 37 o C for 5 minutes. The reaction was initiated by the addition of midazolam (2 µM). After 20 minutes incubation at 37 o C, the same volume of methanol/acetonitrile = 1/1 (v/v) containing etizolam (an internal standard) was added to the incubation mixture to terminate the reaction. After centrifugation, the supernatant was evaporated to dryness. 10 mM PBS (pH 7.4)/methanol/acetonitrile = 10/5/7 (v/v/v) was added to the residue prior to the injection onto the highperformance liquid chromatography (HPLC) column. Our preliminary experiments indicated that the metabolic reaction takes place over a linear range in terms of incubation time and protein concentration under the present experimental conditions. The amount of midazolam and α-hydroxy midazolam was determined by HPLC using a reversed-phase column (4.6 mm x 250 mm TSK gel ODS-80Ts, Tosoh, Tokyo, Japan). The mobile phase consists of 10 mM PBS (pH 7.4)/methanol/acetonitrile = 10/5/7 (v/v/v) and the flow rate was 1 ml/minute. Both midazolam and α-OH midazolam were detected by UV absorption at a wavelength of 220 nm. Figure 1 represents the transcellular transport of vinblastine across Caco-2 monolayers. The transport of vinblastine was linear up to 4 hours. P app for the basal-to-apical compartment (2.86 x 10 -;5 cm/second) was 22-fold higher than that in the opposite direction (1.28 x 10 -;6 cm/second) ( Figure 1 ). This basal-toapical preferential flux was almost completely abolished in the presence of 100 µM verapamil (Figure 1) . Indeed, the P app for apical-to-basal flux (7.52 x 10 -;6 cm/second) was comparable to that in the opposite direction (9.66 x 10 -;6 cm/second).
RESULTS
Transcellular Transport
The concentration-dependent effect of inhibitors on vinblastine flux across the monolayers was determined. As shown in Figure 2 , PSC 833 was the most potent inhibitor of P-gp function, with an IC 50 of 0.1 µM (Table 1) . Although ketoconazole and verapamil significantly reduced P-gp function with an IC 50 of 3 and 30 µM, respectively, the effect of L-754,394 was not significant at a concentration of 1 µM (Figure 2 , Table 1 ). 
Metabolic Studies
The effect of inhibitors on the metabolic conversion of midazolam (2 µM) by human liver and intestinal microsomes is shown in Figure 3 . The metabolic activity of human jejunum microsomes (Lot #HJ005 and #HJ006) was 116 + 3 and 39.3 + 1.9 pmol/minute/mg microsomal protein, respectively, whereas that of human liver microsomes (Lot #HH459) was 233 + 9 pmol/minute/mg microsomal protein. The difference in the absolute value of the metabolic activity may be attributed to the difference in CYP3A4 content. L-754,394 was the most potent inhibitor, with an IC 50 value of 0.005 and 0.05 µM for jejunum and liver microsomes, respectively (Table 1) . Ketoconazole was also a potent inhibitor, with an IC 50 of 0.02 µM for both jejunum and liver microsomes ( Figure 3 and \The ratio of IC 50 for P-gp to that for intestinal CYP3A4 is also summarized in Table 1 . This ratio was more than 200 for L-754,394, and 60-;150 for ketoconazole (Table 1) . Although verapamil inhibited both P-gp and CYP3A4 function, exhibiting comparable IC 50 values (ratio = 1.5), PSC 833 was selective for P-gp (ratio = 0.05) ( Table 1) .
DISCUSSION
In the present study, we determined the selectivity of the effect of verapamil, ketoconazole, PSC 833, and L-754,394 on the function of P-gp and CYP3A4, because the substrates/inhibitors for these proteins mutually overlap. It has been demonstrated that verapamil and PSC 833 are substrates for both CYP3A4 (15,16) and P-gp (17,18), whereas ketoconazole, a CYP3A4 substrate, is not significantly transported via P-gp (19). There are no published reports showing that L-754,394 is transported via P-gp. The results obtained showed that the potency of inhibition of P-gp is in the order PSC 833 >> ketoconazole, verapamil >> L-754,394, whereas that of CYP3A4 is in the order L754,394 > ketoconazole >> PSC 833 and verapamil ( Table 1) . The ratio of the IC 50 for P-gp to that for CYP3A4 was more than 200 for L-754,394, 60-;150 for ketoconazole, 1.5 for verapamil, and 0.05 for PSC 833 (Table 1 ). Collectively, it was shown that PSC 833 and L-754,394 can be used as selective inhibitors of P-gp and CYP3A4, respectively. However, because the selectivity of PSC 833 toward P-gp is marginal (20-fold higher than that for CYP3A4), and because the IC 50 value for P-gp may depend on the experimental conditions (as discussed below), we have to be cautious when interpreting the effect of this inhibitor in any in vivo experiments.
The IC 50 values determined in the present study should be compared with those reported previously. The IC 50 value of PSC 833 (0.15 µM, Table 1 .) was comparable with that previously reported from this laboratory (~0.1 µM) (20). We have examined the effect of PSC 833 on the accumulation of By examining the inhibitory effect of verapamil on the transcellular transport of morpholine-ureaphenylalanine-homophenylalanine-vinylsulfonephenyl (K-02), a peptidomimetic cysteine protease inhibitor, across MDR1 cDNA-transfected MDCK and Caco-2 monolayers, its IC 50 values were determined as 236 + 63 µM and 339 + 19 µM, respectively (21). These values are much higher than those determined in the present study; the IC 50 value for verapamil being found to be ~30 µM (Table 1) . This discrepancy may be accounted for by the fact that the previous authors had added the inhibitors to the basal side only (21), whereas in the present study we added inhibitors to both basal and apical sides. If we liken the action of P-gp to that of a vacuum cleaner, the ligand molecules in the outer leaflet of the lipid bilayer of the plasma membrane are more efficiently extruded into the medium than those in the inner leaflet (22). In the same manner, it is possible that the inhibitors can efficiently reduce the function of P-gp after addition so that they can easily access the outer leaflet of the plasma membrane. Because we also added the inhibitors to the apical side, it is possible that the inhibitory effect was much more potent (in the present study, inhibitor molecules can access P-gp directly from the outer leaflet) than the situation where the inhibitors were added to the basal side only (in the previous studies, inhibitor molecules could access P-gp from the inner leaflet (21)).
In the same manner, the IC 50 of ketoconazole on the transcellular transport of K-02 across the MDR1 cDNA-transfected MDCK monolayers was determined as 119 ± 10 µM (10), which was much higher than that obtained in the present study (~3 µM, Table 1 ). This discrepancy can also be accounted for by the hypothesis described previously. The IC 50 value of ketoconazole determined in the present study is similar to that reported by examining its P-gp-modulating activity in tumor cells (KB-V1 cells) overexpressing this extrusion pump (23). KB-V1 cells were 281-and 256-fold resistant to vinblastine and daunorubicin, respectively, compared with the parental cell line (KB-3-1) (23). Ketoconazole reduced this resistance in a concentration-dependent manner; 2 µM was sufficient to reduce the resistance to antitumor drugs to 27-and 91-fold, respectively (23).
Concerning the effect of inhibitors on metabolic enzymes, it has been reported that verapamil and ketoconazole reduce the function of CYP3A4 with K i values of 41 and 0.015 µM, respectively (15,24,13); these values are consistent with those determined in the present study (20 and 0.02 µM, respectively, Table 1 . These results appear to be reasonable, because, by substituting this k value and incubation time, it was calculated that approximately 25% of the CYP3A4 enzyme should be reduced under the present experimental conditions. The fact that L-754,394 did not significantly inhibit P-gp function up to 1 µM (Figure 2 ) may also be related to its inhibition characteristics. The affinity of L-754,394 itself for CYP3A4 has also been demonstrated to be much lower compared with that of its reactive metabolite (25). The apparent selective inhibition of CYP3A4 by L-754,394 can be attributed to its reactive metabolite (25).
We have no satisfactory explanation to account for the discrepancy in the IC 50 values between the intestinal and liver microsomes (0.005 and 0.05 µM, respectively, Table 1 ), because the CYP3A4 cDNA sequence, along with its metabolic activity, has been demonstrated to be equivalent between these two tissues; Thummel et al. (12) have reported that the K m values of midazolam are 3.58 and 2.74 µM in human intestinal and liver microsomes, respectively. In addition, we had also found the comparable IC 50 values for other inhibitors (verapamil, ketoconazole, and PSC 833; Table 1 ), which may competitively inhibit the function of CYP3A4, between intestine and liver. It is possible that the mode of inhibition of L-754,394 (25) may be related to this difference.
In conclusion, the results of the present study indicate that PSC 833 and L-754394 can be used as selective inhibitors of P-gp and CYP3A4, respectively. By using these selective inhibitors, it should be possible to determine the relative role of Pgp and CYP3A4 in reducing the oral bioavailability of certain drugs.
